Skip to content
10-Q

Quarterly Report

Nugenerex Immuno-oncology, Inc.

0001607062-20-000345

← back to feed
Filed
Dec 15, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2021 · Dec 15, 2020 400.3M sh
Stockholders Equity Q1 2021 · Oct 31, 2020 −$6.01M
Stockholders Equity Q1 2021 · Jul 31, 2020 −$5.84M
Stockholders Equity Q1 2021 · Oct 31, 2019 −$4.63M
Stockholders Equity Q1 2021 · Jul 31, 2019 −$4.38M
Current Liabilities Q1 2021 · Oct 31, 2020 $6.03M
Current Liabilities Q1 2021 · Jul 31, 2020 $5.84M
Current Assets Q1 2021 · Oct 31, 2020 $20.04K
Current Assets Q1 2021 · Jul 31, 2020 $84
Sga Expense Q1 2021 · Oct 31, 2020 $606.13K
Sga Expense Q1 2021 · Oct 31, 2019 $31.8K
Rd Expense Q1 2021 · Oct 31, 2020 $893.64K
Rd Expense Q1 2021 · Oct 31, 2019 $37.38K
Net Income Q1 2021 · Oct 31, 2020 −$1.74M
Net Income Q1 2021 · Oct 31, 2019 −$268.88K
Operating Income Q1 2021 · Oct 31, 2020 −$1.5M
Operating Income Q1 2021 · Oct 31, 2019 −$69.19K